UMHS - University of Michigan Medical Center (Radiation Oncology)
Welcome,         Profile    Billing    Logout  
 2 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Talpaz, Moshe
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Completed
3
56
US
ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
06/23
06/24
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
3
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals, Novartis Pharma AG
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting
1/2
150
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
09/26
09/26
SANRECO, NCT05499013: Study to Assess SLN124 in Patients With Polycythemia Vera

Recruiting
1/2
65
Europe, US, RoW
SLN124, Placebo
Silence Therapeutics plc
Polycythemia Vera
12/24
06/25

Download Options